معرفی
Dr Shevanthi Nayagam serves as a Clinical Senior Lecturer in Hepatology and Public Health at Imperial College London's School of Public Health, holding dual appointments with the MRC Centre for Global Infectious Disease Analysis and Department of Metabolism, Digestion and Reproduction. As a Consultant Hepatologist and Clinical Academic, her interdisciplinary research bridges clinical medicine, mathematical modeling, and health economics to advance viral hepatitis elimination policies, with specialized focus on low- and middle-income country contexts.
Her research program centers on hepatitis B elimination through innovative vaccination strategies and treatment optimization, particularly addressing mother-to-child transmission in resource-limited settings. She leads the multi-country IMPACT-B study evaluating hepatitis B birth dose vaccination effectiveness across Africa and directs the Imperial College Viral Hepatitis Applied Modelling group. Her work integrates clinical insights with policy development through active membership in the PROLIFICA research consortium and Vaccine Impact Modelling Consortium, alongside advisory roles for the World Health Organization on hepatitis guidelines and national strategy formulation for ministries of health.
Analysis of her 2020 publications reveals dual research trajectories: 60% focus on hepatitis B/C elimination through mathematical modeling, cost-effectiveness analysis, and implementation science in LMICs, while 40% address urgent COVID-19 pandemic challenges including hospital capacity planning, emergency department utilization, and health system resilience. Notable intersections include leveraging pandemic response infrastructure for hepatitis elimination opportunities and examining comorbidity interactions between viral hepatitis and SARS-CoV-2.
Dr Nayagam maintains active collaborations with the MRC Centre for Global Infectious Disease Analysis and PROLIFICA research group, which conducts groundbreaking work on hepatitis B-related hepatocellular carcinoma prevention in West Africa through community-based screening and treatment initiatives. Her applied modeling approach directly informs national and global policy decisions for viral hepatitis elimination.
